Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. [electronic resource]
Producer: 20041005Description: 1618-24 p. digitalISSN:- 1078-0432
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms -- drug therapy
- Breast Neoplasms, Male -- drug therapy
- Disease Progression
- Disease-Free Survival
- Environmental Monitoring -- methods
- Enzyme-Linked Immunosorbent Assay
- Female
- Genes, erbB-2
- Humans
- Male
- Neoplasm Metastasis
- Probability
- Receptor, ErbB-2 -- blood
- Time Factors
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.